Berenberg Starts Axsome Therapeutics (AXSM) at Buy

June 10, 2021 6:27 AM EDT
Get Alerts AXSM Hot Sheet
Price: $44.25 -6.59%

Rating Summary:
    12 Buy, 1 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 8 | Down: 33 | New: 7
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Berenberg analyst Esther Hong initiates coverage on Axsome Therapeutics (NASDAQ: AXSM) with a Buy rating and a price target of $112.00.

The analyst commented, "Our Buy recommendation for Axsome Therapeutics reflects two near-term catalysts. First, the FDA will announce its decision on approval of Axsome’s lead product, AXS-05 for the treatment of major depressive disorder, in August. Second, the company expects to submit a new drug application with the FDA this quarter for a second product, AXS-07 for the treatment of migraine."

For an analyst ratings summary and ratings history on Axsome Therapeutics click here. For more ratings news on Axsome Therapeutics click here.

Shares of Axsome Therapeutics closed at $63.50 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Related Entities